
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiat... Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.02 | -0.1638001638 | 12.21 | 12.57 | 10.96 | 1015208 | 11.9236363 | CS |
4 | -2.54 | -17.2437202987 | 14.73 | 15.25 | 10.96 | 666925 | 12.75941651 | CS |
12 | -1.05 | -7.93051359517 | 13.24 | 17.07 | 10.96 | 524362 | 13.60796399 | CS |
26 | -0.41 | -3.25396825397 | 12.6 | 17.7 | 10.96 | 527111 | 13.68684896 | CS |
52 | 1.46 | 13.6067101584 | 10.73 | 17.7 | 7.97 | 598847 | 11.49672835 | CS |
156 | 5.81 | 91.065830721 | 6.38 | 17.7 | 6.015 | 610948 | 9.91439879 | CS |
260 | 5.81 | 91.065830721 | 6.38 | 17.7 | 6.015 | 610948 | 9.91439879 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions